Gemphire Therapeutics (GEMP) Stock Price, News & Analysis

Company Overview

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Key Stats

• Today's Range: $0.74 to $0.79
• 50-Day Range: $0.30 to $6.38
• 52-Week Range: $0.24 to $1.49
• Volume: 215,549 shs
• Average Volume: 127,174 shs
• Market Capitalization: $11.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GEMP Stock Analysis - Frequently Asked Questions

How were Gemphire Therapeutics' earnings last quarter?

Gemphire Therapeutics Inc (NASDAQ:GEMP) released its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15.

When did Gemphire Therapeutics IPO?

Gemphire Therapeutics (GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

What other stocks do shareholders of Gemphire Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemphire Therapeutics investors own include TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Pixelworks (PXLW), Clearside Biomedical (CLSD), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX) and Melinta Therapeutics (MLNT).

Company Calendar

• Last Earnings: 3/15/2019
• Today: 5/03/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GEMP
• CIK: 1638287
• Web: www.gemphire.com
• Phone: 734-245-1700
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,640,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -419.70%
• Return on Assets: -173.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.67
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 1.44

Miscellaneous

• Outstanding Shares: 14,872,000
• Free Float: N/A
• Market Cap: $11.58 million
• Optionable: Not Optionable
• Beta: 2.82